Implications of Efavirenz Pharmacogenetics When Switching from Efavirenz- to Dolutegravir-containing Antiretroviral Regimens

Academic Article

Abstract

  • Many patients switch from efavirenz- to dolutegravir-based regimens. In a phase 1 dolutegravir-efavirenz interaction study, mean dolutegravir minimum concentration decreased by 60% and 85% among CYP2B6 normal and slow/intermediate metabolizers, respectively. Mean efavirenz half-life was 2.7 times greater in slow vs normal metabolizers. Slow metabolizers will experience more prolonged subtherapeutic dolutegravir concentrations.
  • Published In

    Digital Object Identifier (doi)

    Author List

  • Haas DW; Acosta EP
  • Start Page

  • 1820
  • End Page

  • 1822
  • Volume

  • 72
  • Issue

  • 10